Novartis Overview

  • Founded
  • 1996
Founded
  • Status
  • Public
  • Employees
  • 110,000
Employees
  • Stock Symbol
  • NOVN
Stock Symbol
  • Investments
  • 121
  • Share Price
  • $88.83
  • (As of Friday Closing)

Novartis General Information

Description

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
SWX
Primary Office
  • Lichtstrasse 35
  • 4056 Basel
  • Switzerland
+41 061 000 00 00
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$88.83 $88.55 $77.05 - $98.16 $199B 2.25B 4.89M $3.50

Novartis Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 220,141,027 245,145,723 236,263,274 214,333,815
Revenue 49,884,000 49,898,000 48,677,000 46,099,000
EBITDA 15,558,000 15,766,000 14,031,000 19,946,000
Net Income 7,955,000 8,072,000 11,732,000 12,611,000
Total Assets 121,752,000 132,059,000 118,370,000 145,563,000
Total Debt 37,843,000 37,855,000 29,148,000 32,090,000
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Novartis Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis‘s full profile, request access.

Request a free trial

Novartis Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It gene
Pharmaceuticals
Basel, Switzerland
110,000 As of 2021
000000000000

000000 0

magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex
0000000000000
Foster City, CA
00000 As of 0000
00.000
000000&0

00000000

nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor
000000000000000
Brentford, United Kingdom
00000 As of 0000
00000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Novartis Competitors (45)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gilead Sciences Formerly VC-backed Foster City, CA 00000 00.000 000000&0
000000000000000 Corporation Brentford, United Kingdom 00000 00000000000
000000 Corporation New York, NY 00000 000000 - 000
00000 & 00. Corporation Kenilworth, NJ 00000 00000000
00000000000 Formerly PE-Backed Cambridge, United Kingdom 00000 000 00000000 000
You’re viewing 5 of 45 competitors. Get the full list »

Novartis Executive Team (83)

Name Title Board Seat Contact Info
Vasant Narasimhan MD Chief Executive Officer
Richard Saynor Chief Executive Officer, Divisional
Susanne Schaffert Chief Executive Officer, Novartis Oncology
Marie-France Tschudin President
Heinrich Moisa President, Germany
You’re viewing 5 of 83 executive team members. Get the full list »

Novartis Board Members (17)

Name Representing Role Since
0000000 000000 00 Self Board Member 000 0000
000 00000 Self Board Member 000 0000
000000000 000000 Self Board Member 000 0000
0000000 0000000 00 Self Board Member 000 0000
000000000 0000000 Self Board Member 000 0000
You’re viewing 5 of 17 board members. Get the full list »

Novartis Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Novartis Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis‘s full profile, request access.

Request a free trial

Novartis Investments & Acquisitions (121)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000000 29-Mar-2021 0000 00000 Diagnostic Equipment
00000 00000000 18-Mar-2021 00000 00000 00 0000 Drug Delivery
0000 000000000000 02-Mar-2021 00000 00000 00 00000 Other Healthcare Technology Systems
0000 000000000000 24-Feb-2021 00000 00000 00 0000 Biotechnology
TScan Therapeutics 15-Jan-2021 Later Stage VC 00000 Biotechnology
You’re viewing 5 of 121 investments and acquisitions. Get the full list »

Novartis Subsidiaries (16)

Company Name Industry Location Founded
Vedere Biotechnology Cambridge, MA 2019
0000000000 Other Healthcare Technology Systems Phoenix, AZ 0000
00000000000 Pharmaceuticals Les Ulis, France 0000
00000000 0000 0000 Drug Discovery Bannockburn, IL 0000
00000000 000000000 Biotechnology Carlsbad, CA 0000
You’re viewing 5 of 16 subsidiaries. Get the full list »

Novartis Exits (31)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 000000000000 30-Nov-2017 00000 00000 00 00000 Completed
  • 12 buyers
00000000 000000000 01-Aug-2017 00000 00000 00 000.00 Completed
  • 14 buyers
00000 000000000000 14-Jul-2017 000 00000 Completed
  • 00000000
000000000 23-Mar-2017 00000 00000 00 0000 Completed
  • 2 buyers
Arcus Biosciences 29-Aug-2016 Early Stage VC 0000 Completed
  • 10 buyers
You’re viewing 5 of 31 exits. Get the full list »